Objective： To study the effect and safety of graded therapy featuring integrative traditional Chinese and Western medicine for the treatment of hemophilic arthritis. Methods： Forty patients with hemophilic arthritis...Objective： To study the effect and safety of graded therapy featuring integrative traditional Chinese and Western medicine for the treatment of hemophilic arthritis. Methods： Forty patients with hemophilic arthritis were hospitalized randomly, with their blood coagulation factor activity determined by one-stage method and their arthritis classified into 4 stages. The treatment was applied according to the stage of arthritis and finding of intra-articular cavity puncture. For stage I, based on the principle of RICE （rest, ice, compression and elevation）, 1.8 g of Xuefuda （血府达） was medicated orally once per day, intravenous dripping of 250 mL of hemostasis mixture twice a day and 1.2 g of clindamycin per day were also given for hemostasis and anti-inflammation. For stage Ⅱ-Ⅲ, Kangyanling （抗炎灵） was additionally administered via intra-articular cavity injection twice a week, 2 mL every time, for 5-6 times in total. For stage IV, the drug for intra-articular cavity injection was replaced with 25 mg of sodium hyaluronate and the frequency of injection reduced to every two weeks, for 5-6 times in total. Coagulation factors Ⅲ and Ⅳas well as blood plasma were not given in the whole treatment course. Short-term therapeutic effects and adverse reaction in patients were evaluated, and the long-term effects were followed-up after patients left the hospital with 6-month consolidation therapy by Xuefuda. Results： After a 3-week treatment, 33 patients （82.5%） were completely remitted; 5 （12.5%） were partially remitted and 2 （5.0%） un-remitted, setting the short-term effective rate at 95.0% （38 cases）. The 6-month follow-up showed that except for a relapse in 2 and 4 patients of stage Ⅲ and Ⅳrespectively, long-term remission displayed in all the other 34 patients, with the remission sustaining rate being 85.0%. No complication such as an infection, bleeding or aggravating pain occurred in the 215 times intra-articular puncturing conducted in the 40 patients. Normal figures were shown in liver and kidney function, electrolytes, ECG, blood glucose and routine test of blood and urine throughout the course. Conclusion： The graded treatment of integrative medicine for hemophilia with non-blood preparation has a favorable effect and is safe or without any adverse reaction, which opens a high efficacy and new safe path and thinking for the treatment of and deformity prevention in the hemophilic patients.展开更多
Objective： To observe the effect of Xueyou Mixture （血友合剂, XYM） on blood coagulation factors and its safety in treating hemophilia. Metheds： To the randomly selected 65 inpatients of hemophilia, XYM was adminis...Objective： To observe the effect of Xueyou Mixture （血友合剂, XYM） on blood coagulation factors and its safety in treating hemophilia. Metheds： To the randomly selected 65 inpatients of hemophilia, XYM was administered accompanied with intravenous dripping of liver cell growth factor 60-100 mg once a day to protect the liver, with no blood products like concentrated ／~ and FIX factors or blood plasma given. The treatment lasted for 3 weeks. The short-term efficacy and adverse reactions were observed. The long-term efficacy in patients was observed in a follow-up study of 6-12 months after they were discharged from the hospital but continuously took XYM orally. Results： The short-term markedly effective rate in the patients was 95.38% （62/65）. After they were treated for 3 weeks, the level of FⅧ factor activity increased in 56 patients of type A from （3.32 ± 2.21） % to （4.18± 2.23） %, and in 9 of type B from （4.92 ± 1.81） % to （5.64± 1.96） %. Compared with that before treatment, the difference was significant in both of them （P〈0.01）. No obvious adverse reaction was found in the treatment period. The follow-up study showed that in 22 patients of type A, the FⅧ factor activity ratio increased from （3.25±2.11） % to （6.31 ±2.16） %, （8.36±1.05） %, and （16.38±2.71） % in the 2nd, 3rd and 6th month after discharge respectively, all showing significant difference to that before treatment （P〈0.01）; and in 4 patients of type B, it increased from （4.15±2.26） % to 7.8% and 11.6% （mean value） in the 2nd and 6th month respectively. Conclusion： XYM could raise the activity of factors Ⅷ and Ⅸ in patients with hemophilia, and the degree of the rise is related with the duration of the therapy, with no obvious adverse reaction, which strikes out a new path and new train of thinking for the treatment of the disease by nonblood preparation.展开更多
基金Supported by the National Project for Prevention and Treatment of Hemophilia
文摘Objective： To study the effect and safety of graded therapy featuring integrative traditional Chinese and Western medicine for the treatment of hemophilic arthritis. Methods： Forty patients with hemophilic arthritis were hospitalized randomly, with their blood coagulation factor activity determined by one-stage method and their arthritis classified into 4 stages. The treatment was applied according to the stage of arthritis and finding of intra-articular cavity puncture. For stage I, based on the principle of RICE （rest, ice, compression and elevation）, 1.8 g of Xuefuda （血府达） was medicated orally once per day, intravenous dripping of 250 mL of hemostasis mixture twice a day and 1.2 g of clindamycin per day were also given for hemostasis and anti-inflammation. For stage Ⅱ-Ⅲ, Kangyanling （抗炎灵） was additionally administered via intra-articular cavity injection twice a week, 2 mL every time, for 5-6 times in total. For stage IV, the drug for intra-articular cavity injection was replaced with 25 mg of sodium hyaluronate and the frequency of injection reduced to every two weeks, for 5-6 times in total. Coagulation factors Ⅲ and Ⅳas well as blood plasma were not given in the whole treatment course. Short-term therapeutic effects and adverse reaction in patients were evaluated, and the long-term effects were followed-up after patients left the hospital with 6-month consolidation therapy by Xuefuda. Results： After a 3-week treatment, 33 patients （82.5%） were completely remitted; 5 （12.5%） were partially remitted and 2 （5.0%） un-remitted, setting the short-term effective rate at 95.0% （38 cases）. The 6-month follow-up showed that except for a relapse in 2 and 4 patients of stage Ⅲ and Ⅳrespectively, long-term remission displayed in all the other 34 patients, with the remission sustaining rate being 85.0%. No complication such as an infection, bleeding or aggravating pain occurred in the 215 times intra-articular puncturing conducted in the 40 patients. Normal figures were shown in liver and kidney function, electrolytes, ECG, blood glucose and routine test of blood and urine throughout the course. Conclusion： The graded treatment of integrative medicine for hemophilia with non-blood preparation has a favorable effect and is safe or without any adverse reaction, which opens a high efficacy and new safe path and thinking for the treatment of and deformity prevention in the hemophilic patients.
文摘Objective： To observe the effect of Xueyou Mixture （血友合剂, XYM） on blood coagulation factors and its safety in treating hemophilia. Metheds： To the randomly selected 65 inpatients of hemophilia, XYM was administered accompanied with intravenous dripping of liver cell growth factor 60-100 mg once a day to protect the liver, with no blood products like concentrated ／~ and FIX factors or blood plasma given. The treatment lasted for 3 weeks. The short-term efficacy and adverse reactions were observed. The long-term efficacy in patients was observed in a follow-up study of 6-12 months after they were discharged from the hospital but continuously took XYM orally. Results： The short-term markedly effective rate in the patients was 95.38% （62/65）. After they were treated for 3 weeks, the level of FⅧ factor activity increased in 56 patients of type A from （3.32 ± 2.21） % to （4.18± 2.23） %, and in 9 of type B from （4.92 ± 1.81） % to （5.64± 1.96） %. Compared with that before treatment, the difference was significant in both of them （P〈0.01）. No obvious adverse reaction was found in the treatment period. The follow-up study showed that in 22 patients of type A, the FⅧ factor activity ratio increased from （3.25±2.11） % to （6.31 ±2.16） %, （8.36±1.05） %, and （16.38±2.71） % in the 2nd, 3rd and 6th month after discharge respectively, all showing significant difference to that before treatment （P〈0.01）; and in 4 patients of type B, it increased from （4.15±2.26） % to 7.8% and 11.6% （mean value） in the 2nd and 6th month respectively. Conclusion： XYM could raise the activity of factors Ⅷ and Ⅸ in patients with hemophilia, and the degree of the rise is related with the duration of the therapy, with no obvious adverse reaction, which strikes out a new path and new train of thinking for the treatment of the disease by nonblood preparation.
